ARTICLE | Product Development

Naysayers poking at GUSTO again

May 16, 1994 7:00 AM UTC

Genentech Inc. stock fell $2.75 to $46.375 last week as debate on the GUSTO trial of Activase tPA was rekindled, including word that a congressional subcommittee has become involved.

Critics of the drug have contended that the trial, which compared accelerated dosing of Activase with streptokinase, wasn't conducted properly and that the 1 percent absolute benefit provided by tPA doesn't justify its $2,200 cost compared to the $200 cost of SK...